 |
 |
| |||||
|
|
||||||||||
GET A FREE COPY OF THIS GREAT e-BOOK BELOW FOR A LIMITED TIME. Thyroid cancer drug gets US fast-track NEW YORK, Feb 2 (Reuters) - AstraZeneca Plc (AZN.L: Quote, Profile, Research) (AZN.N: Quote, Profile, Research) said on Thursday that the U.S. Food and Drug Administration has granted fast track designation for the investigation of its drug Zactima for the treatment of thyroid cancer. The fast track designation provides the company benefits that may help the drug development and regulatory submission processes and is intended to facilitate the development and speed up the review of investigational drugs that are intended to treat serious or life-threatening conditions. If you have any news or PR related to Thyroid drugs, or any thyroid topics, please email us at news@thyroidtalk.com
FILL IN THE FORM AND DOWNLOAD IT NOW!
